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Abstract: There is little information on chronic obstructive pulmonary disease (COPD) mortality
trends, age of death, or male:female ratio. This study therefore sought to analyze time trends in
mortality with COPD recorded as the underlying cause of death from 1980 through 2017, and with
COPD recorded other than as the underlying cause of death. We conducted an analysis of COPD
deaths in Galicia (Spain) from 1980 through 2017, including those in which COPD was recorded
other than as the underlying cause of death from 2015 through 2017. We calculated the crude and
standardized rates, and analyzed mortality trends using joinpoint regression models. There were
43,234 COPD deaths, with a male:female ratio of 2.4. Median age of death was 82 years. A change
point in the mortality trend was detected in 1996 with a significant decrease across the sexes, reflected
by an annual percentage change of −3.8%. Taking deaths into account in which COPD participated or
contributed without being the underlying cause led to an overall 42% increase in the mortality burden.
The most frequent causes of death when COPD was not considered to be the underlying cause were
bronchopulmonary neoplasms and cardiovascular diseases. COPD mortality has decreased steadily
across the sexes in Galicia since 1996, and age of death has also gradually increased. Multiple-cause
death analysis may help prevent the underestimation of COPD mortality.
Keywords: COPD; trends; mortality; multiple causes
1. Introduction
Chronic obstructive pulmonary disease (COPD) is currently one of the most common
diseases, and its population impact is expected to increase over the coming years [1,2].
Although COPD prevalence varies widely among countries, in Spain, the cross-sectional
study EPISCAN II aimed at estimating COPD prevalence showed that it was 12% among
adults over the age of 40 years [3]. These data are very similar to those reported by the
Global Burden of Disease, which estimated a global prevalence of 11.7% [4]. Furthermore,
COPD gives rise to high mortality, estimated at 3.17 million deaths worldwide in 2015,
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accounting for 5% of total mortality [4]. Available studies indicate that there has been a
decline in COPD mortality since the 1990s, especially among men [5,6], though it is not
known exactly when this decrease began because there are no long-term time series data [7].
Hence, having mortality data based on a large population study conducted in a single area
sharing the same healthcare model would yield valuable information.
Mortality rates due to any cause can be expressed in various ways, depending upon
the objectives to be assessed. The crude mortality rate expresses the relationship between
the number of deaths occurring in any given period and the size of the population among
whom these occur, and is of clinical utility since it allows for local evaluation [8]. The
standardized (or adjusted) mortality rate expresses this relationship, while avoiding the
influence of differences in the structure of the populations analyzed by, for instance, age,
thereby rendering it possible to make comparisons between rates derived from populations
with different age structures (e.g., comparisons between the rates of different countries or
different moments in time) [5,6].
Since the International Classification of Diseases (ICD) was introduced, causes of
death are, on the whole, uniformly registered and are analyzed by the selection of a single
cause, known as the underlying cause [7]. However, it should be noted that, as indicated
by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guide [2], COPD
mortality data are likely underestimated for several reasons. On the one hand, there is a
high rate of underdiagnosis of the disease; on the other, COPD is not included as the cause
of death in many instances where the death is coded as due to another cause, without
considering that the primary cause might indeed be COPD [9–12]. The progressive increase
in the mean age of patients who die of COPD in Spain only serves to further complicate the
problem of accuracy in the coding of cause of death [12,13]. It is often difficult to establish
whether a patient has died “due to” or “with” COPD, in view of this disease’s frequent
coexistence with other cardiovascular comorbidities or neoplasms [13].
The section of the Spanish death statistics report form (Boletín Estadístico de De-
función) addressing health status, as opposed to information of a purely demographic
nature, lists four steps in the dying process (immediate, intermediate, initial or funda-
mental, and other processes), which must be completed. If the certification is performed
properly, the cause shown as initial or fundamental is then chosen as the underlying cause
of death, since it is this disease that is regarded as having initiated the chain of events
which culminated in death [7]. Among patients with COPD, it is essential to ascertain
precisely how their deaths are being certified because this could provide us with a more
comprehensive overview of the problem. To date, this aspect has hardly been studied and
could be of enormous utility for other studies that seek to analyze COPD mortality in Spain
and other countries, since the choice of cause of death meets an international standard.
Accordingly, the aims of this study were to analyze, firstly, the time trend in mortality
due to COPD considered as the underlying cause of death, across a period of almost
40 years (longer than any previous study in Spain), and secondly, the registration of COPD




We performed an analysis of deaths due to COPD among persons aged 35 years and
over in Galicia (NW Spain) across the period 1980–2017, using data sourced from the
Galician Regional Deaths Register. For study purposes, we included both deaths with
COPD shown as the underlying cause across the entire period (mortality “due to COPD”),
and deaths with COPD shown as the immediate cause, intermediate cause, or other process
(mortality “with COPD”) for the years 2015 through 2017. In all cases, COPD was identified
by ICD-9 codes 491, 492, and 496 across the period 1980–1998, and ICD-10 codes J41–44
across the period 1999–2017. In addition, we recorded the main ICD-10 diagnostic codes of
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deceased patients, among whom COPD was shown as the immediate cause, intermediate
cause, or other process.
2.2. Statistical Analysis
(a) Assessment of mortality with COPD as underlying cause of death.
For each year across the period 1980–2017, we calculated COPD-specific mortality
rates by five-year age group, and crude rates and age-standardized rates in the population
aged 35 years and over, by sex.
For the calculation of rates, annual population data for the years 1980–1997 were
drawn from intercensal estimates calculated on the basis of the 1981 and 1991 population
censuses and the 1986, 1996, and 1998 electoral rolls. For the period beginning in 1998,
data were obtained from the Annual Electoral Roll Update, as sourced from the Galician
Statistics Institute. Standardization rate was performed with the direct method using the
2011 Galician census population as standard.
(b) Analysis of multiple causes of mortality due to COPD as a contributing cause of death.
Across the period 2015–2017, we calculated annual crude mortality rates due to COPD
in cases where COPD was included as the underlying cause, and annual crude mortality
rates with COPD in cases where COPD was included as a contributing cause (immediate,
intermediate, or other process) without being shown as the underlying cause on the
death certificate.
(c) Analysis of trends.
To ascertain the time trend in the annual standardized rates, joinpoint regression
models were fitted on the basis of logarithmic transformation of the mortality rates. For
each of the adjusted segments that enable identification of the cut-off points at which
statistically significant changes in the trend take place, we calculated the annual percentage
change (APC) along with its 95% confidence interval (95% CI) [10].
All rates are expressed as cases per 100,000 inhabitants. Data were analyzed with the
Stata 14 software program, and the joinpoint regression was performed using the Joinpoint
Regression software program v4.0.4 (National Cancer Institute, USA) [14,15].
3. Results
3.1. COPD Mortality Trend: Period 1980–2017
Across the period 1980–2017, there were 43,234 deaths due to COPD among the
population aged 35 years and over in Galicia. Of this total, 30,383 deaths occurred in men,
with a male (male:female) mortality ratio (MR) of 2.4. The lowest number of deaths was
observed in 1980, with 597 deaths, and the highest number in 1996, with 1502 deaths. In
2017, there were 1031 deaths due to COPD in Galicia, with an MR of 2.5. Broken down by
age group, the MR was highest in the groups aged 35 through 39 years and 55 through
59 years—that is, for every woman that died, 5.5 men died. The median age of death was
82 years, with this being higher in women than in men (85 vs. 81 years) (Table 1).
Table 1. Deaths and median age of death in the population of Galicia aged 35 years and over, due to COPD coded as




1980–1989 5740 2609 8349
1990–1999 9289 4028 13,317
2000–2009 8823 3633 12,456
2010–2017 6531 2581 9112
Total 30,383 12,851 43,234




Mean 1980–1989 76.0 79.6 77.1
1990–1999 78.2 82.7 79.5
2000–2009 80.7 85.5 82.1
2010–2017 82.3 87.0 83.6
Total 79.4 83.7 80.7
25th percentile 1980–1989 71 75 72
1990–1999 72 78 74
2000–2009 76 81 77
2010–2017 78 83 79
Total 74 79 75
50th percentile 1980–1989 77 81 78
1990–1999 79 84 81
2000–2009 82 87 83
2010–2017 84 88 85
Total 81 85 82
75th percentile 1980–1989 82 85.5 84
1990–1999 85 88 86
2000–2009 87 91 88
2010–2017 89 92 90
Total 86 90 87
In all the years across the period, COPD-specific mortality rates were virtually zero
up to age 45 years, and from age 45 upwards, rose with age in men and women alike
(Figure 1). COPD mortality peaked in persons over the age of 84 years, with an MR of 1.4.




Figure 1. Annual specific mortality rates due to chronic obstructive pulmonary disease (COPD) as 
underlying cause of death in men and women. Galicia, population aged 45 years and over, period 
1980–2017. 
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The trend in the crude COPD mortality rate in the population aged 35 years and
over is shown in Figure 2, both overall and by sex. The mortality rate increased in both
sexes until 1996 and then decreased until 2017, which was when these crude rates, like
the standardized rates (Figure 3), registered the lowest values in the series. The age-
standardized mortality ratio increased during the period, reaching the highest value in
2017 (Figure 4). When the time trends were analyzed in detail (Figure 3), a change point
in the COPD mortality trend was detected in 1996, after which there was a significant
decrease in mortality, reflected in an APC of −3.8% (95% CI: −4.3 to −3.3). This significant
decrease was observed in both men and women (Table 2).
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population aged 35 years and over, period 1980–2017. (APC: annual percentage change; CI: confidence interval).
Sex Change Points (95% CI) Period APC (95% CI) Interpretation
1980–1985 11.5 (6.6; 16.6) Rising
1985 (1983; 1992)
Men 1985–1996 2.0 (0.4; 3.6) Rising
1996 (1992; 2006)
1996–2017 −3.8 (−4.3; −3.3) Falling
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3.2. Trend in Mortality Due to COPD and with COPD: Period 2015–2017
Across the period 2015–2017, COPD was considered to be the underlying cause in
3227 deaths. In contrast, COPD was considered not to have been the underlying cause
but to have participated in the dying process as the immediate or intermediate cause in
1013 deaths, and as the contributing cause—included under “Other processes”—in 1331
deaths (Table 3). Deaths in which COPD participated or contributed to the death process
accounted for 42% of the total burden of mortality due to COPD.
Table 3. Number of deaths in which COPD was shown as underlying cause and as immediate, intermediate, or other
process, without being the underlying cause. Galicia, population aged 35 years and over, period 2015–2017.
Year
Deaths Due to COPD
Considered as
Underlying Cause
COPD Shown as Immediate
or Intermediate Cause but
Not as Underlying Cause
COPD Shown in Other Processes,
but Not as Immediate, Intermediate,
or Underlying Cause
Total
2015 1135 310 447 1892
2016 1064 327 429 1820
2017 1028 376 455 1859
Sum 3227 1013 1331 5571
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In terms of the trend in the crude mortality rates across these 3 years (Figure 5), when
only the underlying cause of death was considered, a decrease of 10.2 percentage points
was observed in the male mortality rate and 2.5 percentage points in the female mortality
rate (6.1 percentage points overall). On the other hand, when the crude mortality rates
considered COPD included in any cause of death, the differences were 2.9 percentage
points in men and 2.5 percentage points in women (2.6 overall).
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Figure 5. Crude mortality rates “due to” COPD (COPD as underlying cause: solid line in the figure)
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Over half of the causes shown as the underlying cause of death when COPD appeared
as immediate, intermediate, or other processes were linked to 10 causes of mortality. The
most frequent ICD-10 codes considered as the underlying cause of death in cases where
COPD was shown as immediate, intermediate, or other processes, but not as the underlying
cause, are depicted in Figure 6. The four most frequent causes coincided in cases where
COPD appeared as an immediate or intermediate cause, but not an underlying cause,
and where COPD appeared under “Other processes”. These were malignant neoplasm
of unspecified part of bronchus or lung (C34.9), ischemic heart disease (I25.9), acute
myocardial infarction (I21.9), and unspecified dementia (F03). In the next six causes, the
following three were repeated: hypertensive heart disease (I11.0); atrial fibrillation (I48.9);
and heart failure, unspecified (I50.9) (Figure 6).
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ave on the certification of multiple-cause mortality on the medical death certificate.
In 1996, there was a change in the mortality trend, with a continuous annual decr as of
almost 4% until 2017. When it comes to multiple causes of death, C P is fr
in other causes of dea that are n t consi ered to be th underlying caus ,
something that may serve to underestimate the true current i fluence of this disease n
mortality atistics, and could have implications in any future COPD mortality studies
conducted using multiple-mortality coding.
i t r r t t l t t rt lit ti ri l i
i r e [5 7]. ere is l e st , un ert e e - s et l. i
n al sia, hich incl es ata since 1975, b t it en s in 2010 [7]. ational ata incl e
in other international studies only date fro 1990 on ards [5,6]. Fro 1980, the rise in
COPD mortality in Galicia is seen to gradually level off until 1995 (before reaching the
inflection point in 1996)—a trend that is more clearly visible among men. Both trends are
evident in men and women, and display no differences by sex. These data are in line with
existing literature. Another study by Lopez-Campos et al. analyzed the mortality trends of
27 European countries from 1994 through 2000, reporting a downward trend in both sexes.
While the mortality rate in men fell from 90.1 cases per 100,000 inhabitants in 1994 to 61.3
in 2010, the decrease was less marked in women, going from 27.0 to 25.2 [5]. For Spain, this
study indicates that the COPD mortality rate decreased across the study period in men
and women alike. The study conducted by the same author in Andalusia reports similar
results, with a downward trend in the period 1994–2010, in men (from 149.1 to 98.0 cases
per 100,000 inhabitants) and women (from 26.4 to 12.0) [7]. However, the trend in the first
two decades in Andalusia shows a bimodal behavior pattern, with a clear decrease from
1975 through 1981, and an increase until 1993 in women and 1997 in men, which is when
the downward trends begin. Similar to our study, the data from Andalusia show a more
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pronounced rise in the first half of the 1980s and a more gradual rise until the mid-1990s,
marking the start of the clear downward trend [7].
Many reasons account for this change in trend from the mid-1990s onwards. From
a clinical standpoint, mention should be made of the increasingly generalized use of
long-acting bronchodilators in these patients, and of non-invasive mechanical ventilation
in patients with hypercapnic respiratory failure, as well as enhanced knowledge of the
disease, its control, and the management of its comorbidities [7,16,17]. Another possible
explanation might lie in the change in ICD codes, following the switch from the ninth to
the tenth revision that took place during this decade. Even so, there are studies which have
shown that this is not the cause of under-registration of COPD mortality [18,19], something
that goes to reinforce both the findings of this and other similar studies, and the reasons for
it explained above.
In addition to advances in the care of the disease, the measures being implemented in
the majority of the most developed countries could positively influence the trends described
in this and other studies. These measures focus on targeting smoking habit, environmental
pollution and occupational exposures to different types of smoke and other toxics, reducing
underdiagnosis of the disease, and controlling the different respiratory and non-respiratory
comorbidities [20]. Different authors have estimated that this downward trend may become
markedly steeper over the following two decades, so that by or around 2040, most affected
patients may die “with” rather than “due to” COPD [5,21]. This is further reinforced
by the median age of death—across the period 2010 through 2017, the median age of
death was 81 years in men and 85 in women, being equal to the life expectancy of men
and slightly lower than that of women (National Statistics Institute/Instituto National de
Statistical (INE)).
This finding heightens the relevance of analyzing the completion of death certificates.
In this study, just over 40% of death certificates included COPD as part of the dying process,
implying that the real burden of the disease in the mortality statistics is considerably higher.
In clinical hospital cohort studies published in Spain, the most frequent causes of mortality
reported in patients with COPD are neoplasms and cardiovascular diseases [22,23]. This is
in line with our study in that when COPD is not considered to be the underlying cause of
death, most of the patients die due to neoplasms (essentially bronchopulmonary), different
cardiovascular diseases, or dementias. Although this finding has already been observed
in studies undertaken in other countries [11,12], it is evident that analysis of mortality
data, if not completed with multiple causes, does not reflect the real burden of COPD at a
population level. This is an increasingly important problem in COPD, both for the reasons
discussed and the progressive increase in the age of death, which in our study was around
two years per decade. It is therefore essential to have all data shown on the certificates
(multiple causes of death), and to analyze these in order to better understand how the
different diseases making up the current mortality scenario behave [8,12]. Although this
multiple coding was available to us for a period of only 3 years and the underlying cause-
based mortality trend is also dropping (particularly in men), when we used multiple-cause
coding, the drop nonetheless appeared to be much smaller, confirming that it is becoming
increasingly more frequent for COPD patients to die “with” rather than “due to” COPD.
This study displays a number of strengths. Firstly, it analyzes the overall data of a
stand-alone health system covering a catchment population of approximately 2,700,000.
This study involved no sampling, since it included the entire stratum of deceased COPD
patients (with the ICD codes indicated) across the whole period analyzed and was thus
fully representative. It should be noted that Galicia was the first Spanish autonomous
region, and indeed one of the first regions in Europe, to have universal electronic health
records for its entire healthcare system, with the possibility of accessing these to correct
important incongruences or inconsistencies in death certificates, thus equipping it with one
of the most advanced health information systems in Europe. When it comes to cause of
death, the fact that the study targeted a single health service means that, even though there
might conceivably be errors in the completion of death certificates, such errors would be
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expected to affect all the years recorded in the same way. Likewise, any variations would
be expected to be fewer than if sampling had been performed or if different health services,
possibly with a different diagnostic or registration criterion, had been included.
This study also has limitations. It is a descriptive study, and we have no data on
factors that have an influence on COPD mortality, such as smoking habit, medication use,
and patients’ previous admissions. Although this information might have been of great
utility, it in no way detracts from the validity of the study, whose main aim was to ascertain
the COPD mortality trend and the possible influence of multiple causes of death on the
death register. A further limitation is that very few years—only three—were analyzed to
assess the impact of multiple-cause coding. Even so, we feel that these provide sufficient
evidence of how COPD mortality may be affected by a new system of analysis that includes
multiple causes.
In conclusion, since 1996, COPD mortality has fallen steadily in Galicia in both sexes,
without variations in the male:female mortality ratio over time. It is extremely positive that
patients’ median age of death is practically equal to their life expectancy—something that
reflects the effectiveness of these treatments and indirectly indicates that clinical practice
is proving successful. Furthermore, the new multiple-mortality coding system may pose
a real challenge to studies which seek to analyze COPD mortality, making it necessary
to collect data not only on the underlying cause of death, but also on the immediate and
intermediate cause or other processes if one wishes to avoid underestimating this particular
cause of death.
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